Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.84B
Market cap1.84B
Price-Earnings ratio
-3.93
Price-Earnings ratio-3.93
Dividend yield
Dividend yield
Average volume
3.44M
Average volume3.44M
High today
$13.44
High today$13.44
Low today
$13.00
Low today$13.00
Open price
$13.26
Open price$13.26
Volume
2.45M
Volume2.45M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

As of today, Intellia Therapeutics(NTLA) shares are valued at $13.28. The company's market cap stands at 1.84B, with a P/E ratio of -3.93.

During the trading session on 2026-08-27, Intellia Therapeutics(NTLA) shares reached a daily high of $13.44 and a low of $13.00. At a current price of $13.28, the stock is +2.2% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 2.45M, compared to an average daily volume of 3.44M.

The stock's 52-week range extends from a low of $7.95 to a high of $28.25.

The stock's 52-week range extends from a low of $7.95 to a high of $28.25.

NTLA News

Simply Wall St 1d
Intellia Therapeutics Stock May Be Fully Priced Despite Its 92% Slide

Intellia Therapeutics stock has rebounded over the past year, yet its longer term track record and current valuation checks point to a much less flattering pict...

Intellia Therapeutics Stock May Be Fully Priced Despite Its 92% Slide
TipRanks 3d
Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today

20:17 EDT Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, ma...

TipRanks 6d
Intellia Therapeutics Earnings Call Highlights Clinical Momentum

Intellia Therapeutics Inc ((NTLA)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock power...

Analyst ratings

53%

of 19 ratings
Buy
52.6%
Hold
31.6%
Sell
15.8%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.